

## Review of: "Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases"

Sivakumar Sivagurunthan Moni

Potential competing interests: No potential competing interests to declare.

The article entitled <u>Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases" is an interesting study that can be accepted. My comments are:</u>

- 1. What specific data supports the safety and efficacy of IBDV in humans?
- 2. How does IBDV's effectiveness in combating various human viruses compare to existing standard-of-care treatments?
- 3. The article proposes a post-infection plan "B" using IBDV. However, is there sufficient evidence to support that this approach would be as effective in pre-emptive or preventative scenarios, especially for future pandemics?
- 4. While the article outlines a strategy for IBDV's regulatory approval and production, does it sufficiently address the challenges of global distribution?
- 5. Overall, the subject area and demonstrated works are good. But the manuscript should be proofread through standard proofreading before publication.

Qeios ID: SNKU5X · https://doi.org/10.32388/SNKU5X